Evaluation of Patients Treated with Natalizumab for Progressive Multifocal LeukoencephalopathyTarek A Yousry, David B. Clifford, Eugene O. Major et al.|New England Journal of Medicine|2006Cited by 792
The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression modelRandall J. Bateman, Chengjie Xiong, Tammie L.S. Benzinger et al.|Alzheimer s & Dementia|2016Cited by 303
Treatment of Progressive Multifocal Leukoencephalopathy Associated with NatalizumabWerner Wenning, Ralf Gold, Aiden Haghikia et al.|New England Journal of Medicine|2009Cited by 178
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trialSusan Mills, Randall J. Bateman, J. Mallmann et al.|Revue Neurologique|2013Cited by 136
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Bruno Stankoff, Anne‐Laure Dubessy et al.|Multiple Sclerosis Journal|2022Cited by 46